KR20110015516A - 혈관신생억제 작용을 갖는 항종양 테르페노이드 약학적 조성물 ‘아비실린’ - Google Patents
혈관신생억제 작용을 갖는 항종양 테르페노이드 약학적 조성물 ‘아비실린’ Download PDFInfo
- Publication number
- KR20110015516A KR20110015516A KR1020107022802A KR20107022802A KR20110015516A KR 20110015516 A KR20110015516 A KR 20110015516A KR 1020107022802 A KR1020107022802 A KR 1020107022802A KR 20107022802 A KR20107022802 A KR 20107022802A KR 20110015516 A KR20110015516 A KR 20110015516A
- Authority
- KR
- South Korea
- Prior art keywords
- abicillin
- tumor
- angiogenesis
- activity
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 37
- 150000003505 terpenes Chemical class 0.000 title claims abstract description 30
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- 230000002401 inhibitory effect Effects 0.000 title description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 27
- 230000005764 inhibitory process Effects 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 235000007586 terpenes Nutrition 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- 230000002001 anti-metastasis Effects 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 8
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 claims abstract description 6
- 230000009471 action Effects 0.000 claims abstract description 5
- 150000004141 diterpene derivatives Chemical class 0.000 claims abstract description 5
- 229930003658 monoterpene Natural products 0.000 claims abstract description 5
- 230000007935 neutral effect Effects 0.000 claims abstract description 4
- 150000002989 phenols Chemical class 0.000 claims abstract description 4
- 235000003441 saturated fatty acids Nutrition 0.000 claims abstract description 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims abstract description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 4
- 241000218641 Pinaceae Species 0.000 claims abstract description 3
- 229940115397 bornyl acetate Drugs 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 235000011613 Pinus brutia Nutrition 0.000 claims description 4
- 239000000824 cytostatic agent Substances 0.000 claims description 4
- 230000001085 cytostatic effect Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000004005 microsphere Substances 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 230000009462 endogenous apoptosis Effects 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 21
- 239000003795 chemical substances by application Substances 0.000 abstract description 17
- 230000006907 apoptotic process Effects 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 10
- 230000002491 angiogenic effect Effects 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 7
- 230000029663 wound healing Effects 0.000 abstract description 6
- 241000218631 Coniferophyta Species 0.000 abstract description 5
- 208000035475 disorder Diseases 0.000 abstract description 5
- 230000006698 induction Effects 0.000 abstract description 5
- 230000000771 oncological effect Effects 0.000 abstract description 3
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract description 3
- -1 terpene compound Chemical class 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 50
- 241001465754 Metazoa Species 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 28
- 229940079593 drug Drugs 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 239000002246 antineoplastic agent Substances 0.000 description 15
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 15
- 229960004316 cisplatin Drugs 0.000 description 15
- 206010027476 Metastases Diseases 0.000 description 14
- 230000001772 anti-angiogenic effect Effects 0.000 description 13
- 210000002889 endothelial cell Anatomy 0.000 description 13
- 230000009401 metastasis Effects 0.000 description 13
- 239000004037 angiogenesis inhibitor Substances 0.000 description 12
- 201000001441 melanoma Diseases 0.000 description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 10
- 201000010897 colon adenocarcinoma Diseases 0.000 description 10
- 208000029742 colonic neoplasm Diseases 0.000 description 10
- 201000005202 lung cancer Diseases 0.000 description 10
- 208000020816 lung neoplasm Diseases 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 238000010171 animal model Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000000306 recurrent effect Effects 0.000 description 6
- 238000002271 resection Methods 0.000 description 6
- 238000011287 therapeutic dose Methods 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 108090000672 Annexin A5 Proteins 0.000 description 5
- 102000004121 Annexin A5 Human genes 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 229940120638 avastin Drugs 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 201000008274 breast adenocarcinoma Diseases 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- 102000009840 Angiopoietins Human genes 0.000 description 3
- 108010009906 Angiopoietins Proteins 0.000 description 3
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000020238 sunflower seed Nutrition 0.000 description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 241000202349 Taxus brevifolia Species 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 231100000065 noncytotoxic Toxicity 0.000 description 2
- 230000002020 noncytotoxic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000218642 Abies Species 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 102100034724 Lipocalin-1 Human genes 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 241000896103 Pinus sibirica Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010006830 TIE receptors Proteins 0.000 description 1
- 102000005450 TIE receptors Human genes 0.000 description 1
- 102000012753 TIE-2 Receptor Human genes 0.000 description 1
- 108010090091 TIE-2 Receptor Proteins 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940124642 endogenous agent Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 150000002773 monoterpene derivatives Chemical group 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000010046 negative regulation of endothelial cell proliferation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000404 nontoxic agent Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000010304 tumor cell viability Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU2008/000147 WO2009113902A1 (ru) | 2008-03-14 | 2008-03-14 | Пpoтивooпyxoлeвaя терпеноидная фармацевтическая композиция «aбиcилин» с ангиогенезингибирующим дeйcтвиeм |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20110015516A true KR20110015516A (ko) | 2011-02-16 |
Family
ID=41065440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107022802A Ceased KR20110015516A (ko) | 2008-03-14 | 2008-03-14 | 혈관신생억제 작용을 갖는 항종양 테르페노이드 약학적 조성물 ‘아비실린’ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20110165271A1 (enExample) |
| EP (1) | EP2275112A4 (enExample) |
| JP (1) | JP2011514354A (enExample) |
| KR (1) | KR20110015516A (enExample) |
| CN (1) | CN102036672A (enExample) |
| CA (1) | CA2727792C (enExample) |
| EA (1) | EA017659B1 (enExample) |
| IL (1) | IL208092A (enExample) |
| WO (1) | WO2009113902A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102657660A (zh) * | 2012-04-28 | 2012-09-12 | 上海交通大学医学院 | 三萜类化合物在制备抑制血管生成药物中的应用 |
| WO2013176564A1 (ru) * | 2012-05-25 | 2013-11-28 | Общество С Ограниченной Ответственностью "Инитиум-Фарм" | Терпеноидное средство для профилактики и лечения атеросклероза и коррекции метаболического синдрома |
| RU2634253C1 (ru) * | 2016-12-22 | 2017-10-24 | Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) | Антиангиогенное лекарственное средство |
| RU2747147C1 (ru) * | 2020-06-22 | 2021-04-28 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Фармацевтическая композиция, проявляющая цитотоксичность в отношении клеток карциномы толстой кишки человека |
| RU2765414C1 (ru) * | 2020-09-30 | 2022-01-31 | Ооо "Инитиум-Фарм" | Способ стимуляции митофагии и аутофагии в клетках, способ стимуляции аутофагии или митофагии для лечения состояния, ассоциированного с митохондриальной дисфункцией |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2051900C1 (ru) | 1991-02-15 | 1996-01-10 | Санкио Компани Лимитед | 5-амино-1-гидроксиметилциклопентан-1,2,3,4-тетраол, 2-амино-4-гидроксиметил-3a,5,6,6a-тетрагидро-4н-циклопент-[d]-оксазол-4,5,6-триол, их фармацевтически приемлемые соли и способы их получения |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE122004000008I1 (de) * | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5488116A (en) | 1992-03-30 | 1996-01-30 | Sloan-Kettering Institute For Cancer Research | Total synthesis of taxol and analogues thereof |
| RU2054945C1 (ru) * | 1995-06-28 | 1996-02-27 | Нина Максимовна Пинигина | Средство "абисил-1", обладающее противовоспалительной, антибактериальной и ранозаживляющей активностью |
| RU2196581C2 (ru) | 2000-05-04 | 2003-01-20 | Колесников Андрей Григорьевич | Способ получения r-тетраола, обладающего противоопухолевой активностью |
| AU784231B2 (en) | 2000-06-23 | 2006-02-23 | Schering Aktiengesellschaft | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II) |
| RU2198653C1 (ru) * | 2002-03-29 | 2003-02-20 | Пинигина Нина Максимовна | Полиактивные ректальные или вагинальные суппозитории на основе природных терпенов, обогащенных монотерпеноидами, для лечения и/или профилактики урологических, проктологических или гинекологических заболеваний |
| AU2003264192A1 (en) * | 2002-08-30 | 2004-03-19 | Biopharmacopae Design International Inc. | Plant extracts for treatment of angiogenesis and metastasis |
| RU2244928C2 (ru) | 2003-02-19 | 2005-01-20 | Пинигина Нина Максимовна | Эндогенная фармацевтическая композиция, полученная на основе целенаправленной активации гуморальных медиаторов нервных окончаний коры головного мозга |
| RU2338547C1 (ru) * | 2007-02-16 | 2008-11-20 | Людмила Анатольевна Лацерус | Полиактивная терпеноидная субстанция абисил-2, фармацевтическая композиция на ее основе и способы ее применения |
-
2008
- 2008-03-14 EP EP08873343A patent/EP2275112A4/en not_active Ceased
- 2008-03-14 JP JP2010550631A patent/JP2011514354A/ja active Pending
- 2008-03-14 WO PCT/RU2008/000147 patent/WO2009113902A1/ru not_active Ceased
- 2008-03-14 US US12/922,338 patent/US20110165271A1/en not_active Abandoned
- 2008-03-14 CA CA2727792A patent/CA2727792C/en active Active
- 2008-03-14 KR KR1020107022802A patent/KR20110015516A/ko not_active Ceased
- 2008-03-14 EA EA201001289A patent/EA017659B1/ru not_active IP Right Cessation
- 2008-03-14 CN CN2008801288610A patent/CN102036672A/zh active Pending
-
2010
- 2010-09-12 IL IL208092A patent/IL208092A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL208092A0 (en) | 2010-12-30 |
| EA201001289A1 (ru) | 2011-04-29 |
| WO2009113902A1 (ru) | 2009-09-17 |
| EP2275112A4 (en) | 2011-10-12 |
| CA2727792A1 (en) | 2009-09-17 |
| JP2011514354A (ja) | 2011-05-06 |
| IL208092A (en) | 2015-07-30 |
| US20110165271A1 (en) | 2011-07-07 |
| CA2727792C (en) | 2017-07-25 |
| EP2275112A1 (en) | 2011-01-19 |
| CN102036672A (zh) | 2011-04-27 |
| EA017659B1 (ru) | 2013-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bailly | Potential use of edaravone to reduce specific side effects of chemo-, radio-and immuno-therapy of cancers | |
| Mancuso et al. | Artemisinin-type drugs for the treatment of hematological malignancies | |
| Venugopal et al. | Phytochemicals in diets for breast cancer prevention: The importance of resveratrol and ursolic acid | |
| Fraguas-Sánchez et al. | Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles | |
| US8691870B2 (en) | Use of isothiocyanates for treating cancer | |
| Liang et al. | The synergism of natural compounds and conventional therapeutics against colorectal cancer progression and metastasis | |
| KR20110015516A (ko) | 혈관신생억제 작용을 갖는 항종양 테르페노이드 약학적 조성물 ‘아비실린’ | |
| Xiong et al. | Piceatannol-3′-O-β-D-glucopyranoside attenuates colistin-induced neurotoxicity by suppressing oxidative stress via the NRF2/HO-1 pathway | |
| Sun et al. | Silibinin suppresses bladder cancer cell malignancy and chemoresistance in an NF-κB signal-dependent and signal-independent manner | |
| CN109350613B (zh) | 一种治疗癌症的姜黄素复方制剂 | |
| US20050288378A1 (en) | Cancer chemotherapy | |
| JP2016530326A (ja) | ロクベンシモツケソウ抽出物及びその用途 | |
| KR102434881B1 (ko) | 천화분, 백선피 및 상백피를 포함하는 암 및 내성암에 대한 약학적 조성물 | |
| Cheng et al. | The potential of neural stem cell as vehicle to deliver quercus infectoria extract to glioma cell in vitro | |
| Papakotsi et al. | Alaska’s Flora as a Treatment for Cancer | |
| Birla et al. | Phytochemical and anticarcinogenic evaluation of Triphala powder extract, against melanoma cell line induced skin cancer in rats | |
| JP2014224148A (ja) | 血管新生阻害作用を示す抗腫瘍テルペノイド医薬組成物アビシリン | |
| TWI728551B (zh) | 藥學組合物用於治療與半乳糖凝集素-１活化相關癌症之用途 | |
| US20060110467A1 (en) | Cancer chemotherapy | |
| CN114533882B (zh) | 一类治疗癌症的生育三烯酚类物质组合物 | |
| Nair et al. | Multifaceted role of phytoconstituents based nano drug delivery systems in combating TNBC: A paradigm shift from chemical to natural | |
| Potdar et al. | Case study of notable plant-based drugs | |
| WO2021006822A1 (en) | Pharmaceutical compositions having synergistic effects of natural extracts for cancer treatment undergoing chemotherapy | |
| Collevecchio et al. | Auraptene: a survey of the last three years of intense research | |
| EP1549330B1 (en) | Pomolic acid for treating multidrug resistant tumours |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20101012 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20130313 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20140424 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20150120 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20140424 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |